Reference : WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid art...
Scientific journals : Article
Human health sciences : Rheumatology
WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis
Emery, P. [ > > ]
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Appelboom, T. [ > > ]
Breedveld, F. C. [ > > ]
Edelmann, E. [ > > ]
Kekow, J. [ > > ]
Malaise, Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie >]
Mola, E. M. [ > > ]
Montecucco, C. [ > > ]
Sanda, M. [ > > ]
Sany, J. [ > > ]
Scott, D. L. [ > > ]
Serni, U. [ > > ]
Seydoux, G. [ > > ]
Oxford University Press
Yes (verified by ORBi)
United Kingdom
[en] Monoclonal Antibodies ; Antirheumatic Agents ; Immunoglobulin G ; Tumor Necrosis Factor
[en] Severe adult rheumatoid arthritis is a cause of progressive disability and
increased mortality across Europe. A cure for the disease remains elusive, but
control of symptoms and maintenance of individual independence is possible.
Anti-cytokine therapies offer a new approach to disease management. They are
effective after the failure of full doses of methotrexate, and are at least as
effective as methotrexate in retarding the progression of radiological changes.
Until more is known about the long-term safety and efficacy of these drugs they
should be reserved for patients with severe disease who are progressing despite
adequate doses of methotrexate or other disease-modifying anti-rheumatic drugs.
They should be continued until therapeutic failure or intolerance. A
comprehensive health economic evaluation is needed to optimally direct the use of
these drugs. This should be undertaken when long-term safety and efficacy studies
are completed.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Restricted access
Malaise_2001_Rheumatology(Oxford)_699-702.pdfPublisher postprint315.63 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.